Outlook Therapeutics Inc (OTLK): Thermo, a couple questions. If there...

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	92
Posts	20563
Boards Moderated	0
Alias Born	09/06/2006

exwannabe

Re: thermo post# 991

Saturday, 08/31/2024 10:14:11 AM

Saturday, August 31, 2024 10:14:11 AM

Thermo, a couple questions.

If there is a financing, is it safe to say it would be after results?

Also, they mentioned product already on hand for launch. I assume this has been expensed to R&D so will juice the GM and bottom line a bit. More importantly, cash flow. Is it enough to be material?

TIA

Keep Last Read

Replies (1) Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent OTLK News

Form 8-K - Current report • Edgar (US Regulatory) • 05/26/2026 11:15:41 AM
Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg) • GlobeNewswire Inc. • 05/26/2026 11:00:00 AM
Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2026 09:03:14 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 08:31:12 PM
Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/15/2026 08:05:00 PM
Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/13/2026 09:12:56 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 08:36:26 PM
Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 05/07/2026 08:24:31 PM
Form 8-K - Current report • Edgar (US Regulatory) • 04/23/2026 08:30:39 PM
Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering • GlobeNewswire Inc. • 04/23/2026 08:05:00 PM
Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/23/2026 11:30:17 AM
Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 04/21/2026 08:15:44 PM
Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) • GlobeNewswire Inc. • 04/21/2026 01:05:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 08:15:24 PM
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA • GlobeNewswire Inc. • 04/07/2026 12:50:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 09:04:56 PM
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering • GlobeNewswire Inc. • 03/25/2026 08:05:00 PM
Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering • GlobeNewswire Inc. • 03/24/2026 11:00:00 AM
Outlook Therapeutics Announces Proposed Public Offering • GlobeNewswire Inc. • 03/23/2026 09:30:00 PM
Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/23/2026 09:18:35 PM
Form 8-K - Current report • Edgar (US Regulatory) • 03/16/2026 01:00:28 PM
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note • GlobeNewswire Inc. • 03/16/2026 12:05:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 03/10/2026 08:30:54 PM
Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 10:01:18 PM

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Detailed Quote

Recent OTLK News

More OTLK News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent OTLK News

Go Ad-Free